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AbstrAct
background: The objective of this study was To determine the dose volume parameters predicting acute haematological 
toxicity in carcinoma cervix patients undergoing concurrent chemoradiotherapy.
Materials and methods: all patients that presented to the hospital between Jan 2019 and Dec 2019 were prospectively 
analyzed. patients diagnosed to have carcinoma cervix and planned for concurrent chemoradiation by volumetric modulated 
arc therapy (VMaT) were included for analysis. patients were assessed at baseline and every week during treatment for acute 
haematological toxicities. Dose volume parameters from treatment plans were correlated with rTOG grade of haematological 
toxicities.
results: a total of 34 patients diagnosed to have squamous cell carcinoma of cervix were treated by radical radiotherapy by 
VMaT technique and concurrent chemotherapy. The most common stage of presentation was stage IIB (61.7%). 29 patients 
(85.2%) completed five cycles of weekly cisplatin. statistical analysis for sensitivity and specificity of dosimetric parameters 
was performed using receiver operating characteristic (rOc) curve. The probability of developing bone marrow toxicity was 
analyzed using T test. Mean dose to bone marrow exceeding 28.5 Gy was significantly associated with bone marrow toxicity 
(sensitivity — 82.4%, specificity — 70.6%). On analyzing dose volume parameters, volume of bone marrow receiving 20 Gy, 
30 Gy and 40 Gy (V20, V30 and V40) more than 71.75%, and 49.75% and 22.85%, respectively, was significantly associated with 
bone marrow toxicity. 
conclusions: Our study concludes that mean dose to bone marrow exceeding 28.5 Gy has high sensitivity and specificity for 
predicting bone marrow toxicity in patients receiving IMrT. Volume of bone marrow receiving 20 Gy, 30 Gy and 40 Gy signifi-
cantly correlated with acute haematological toxicity.
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Concurrent chemoradiation therapy (CCRT) 
combined with brachytherapy is the current stan-
dard of care for the management of locally ad-
vanced carcinoma cervix [1, 2]. More than 40% of 
active bone marrow is located in the pelvic region 
which receives varying degree of exposure during 
pelvic radiotherapy for cervical cancer resulting in 
acute hematological toxicity [3]. This acute toxicity 
is more severe with combined therapy compared 
with radiation therapy alone [4].
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Over the past few years, there has been rising 
interest in using Intensity Modulated Radiotherapy 
(IMRT) for the treatment of gynecologic cancers to 
reduce side effects, mainly related to the bowel and 
bladder [5, 6]. Non bone marrow sparing IMRT 
can result in significant volume of marrow receiv-
ing low dose of radiation [7]. There is limited data 
regarding predictors of acute hematological toxicity 
in carcinoma cervix patients receiving concurrent 
chemoradiotherapy with IMRT. We report the dose 
volume parameters associated with increased bone 
marrow toxicity in that scenario. 
Materials and methods
This study was a prospective observational study 
that included patients treated between January 2019 
and December 2019. The study was approved by 
the institutional scientific and ethics committee. 
Patients diagnosed to have Carcinoma Cervix and 
planned for concurrent chemoradiation by IMRT 
were included for analysis. Patients that required 
postoperative adjuvant radiation, extended field ir-
radiation and those who had not received chemo-
therapy were excluded from analysis. Patients were 
assessed at baseline and every week during treat-
ment for acute hematological toxicities. Bone mar-
row dose volume parameters from treatment plans 
(mean dose, V20, V30 and V40) were correlated 
with RTOG grade of acute hematological toxicities.
simulation 
A CT scan of each patient in the treatment posi-
tion was obtained using our departmental scanner 
(Philips Brilliance, Netherlands). The scan param-
eters consisted of a large field-of-view pelvic proto-
col with a 3-mm-slice thickness. The CT scans were 
obtained from the L1 vertebral body to 5 cm below 
the ischial tuberosities. Intravenous contrast was 
administered to all patients before CT. In addition, 
all patients were immobilized with a thermoplastic 
mask. 
radiotherapy treatment
All patients were treated by the Rapid Arc IMRT 
technique (Elekta Synergy LINAC). The clinical 
target volume (CTV) and critical organs were con-
toured on individual axial CT slices in all patients. 
The clinical target volume was defined as the gross 
tumor plus areas containing potential microscopic 
disease, including the cervix and uterus (if present), 
the superior third of the vagina (or superior half 
of the vagina, if clinically involved), the parame-
tria, and the regional lymph nodes. The planning 
margins consisted of 15 mm around the cervix and 
uterus, 10 mm around the vagina and parametria, 
and a 5- to 7-mm margin around the nodal re-
gions. The prescribed dose to the planning target 
volume (PTV) was 50 Gy in 2Gy daily fractions. 
The organs at risk included the bladder, bowel, rec-
tum and femur heads. For each patient, freehand 
contours of the low-density regions inside the bone 
were contoured as the surrogate for bone marrow 
(Fig.  1). The window was adjusted to bone range 
while contouring to bring uniformity. To eliminate 
inter observer variations, all contouring was done 
by a single physician and verified by another physi-
cian for all patients. The contouring began at 2 cm 
above the uppermost border of PTV and ended at 
2 cm below the lower border of the PTV. No con-
straint was prescribed to the pelvic bone marrow 
as the bone marrow was not defined as an OAR. 
Dose–volume histograms (DVHs) corresponding 
to the delivered IMRT plan were generated and the 
volume of bone marrow receiving 20, 30 and 40 Gy 
(V20, V30, and V40, respectively) was quantified. 
Brachytherapy 
As per the institutional protocol, all patients re-
ceived the first fraction of HDR brachytherapy after 
three weeks from the start of treatment (after 30 Gy 
EBRT). The total dose prescribed was 21 Gy in 3 
fractions, 7 Gy per fraction to point A, one fraction 
per week. The technique used for brachytherapy 
was 3 dimensional image guided brachytherapy. 
Figure 1. Free hand contouring of the inner cortex of the 
pelvic bone for bone marrow delineation
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chemotherapy 
All patients were planned to receive weekly cispl-
atin at a dose of 40 mg/m2 along with external beam 
radiotherapy. Cisplatin was typically held under the 
following conditions: white blood count (WBC) 
2.0 × 109/L, absolute neutrophil count (ANC) 
1.0 × 109/L, platelet count 50 × 109/L, or creatinine 
clearance less than 50 mL/min.
Toxicity 
Patients were assessed at baseline and every week 
during treatment for acute hematological toxici-
ties. Dose volume parameters from treatment plans 
(mean dose, V20, V30 and V40) were correlated 
with RTOG grade of acute hematological toxicities. 
Overall toxicity was defined as haematological tox-
icity manifesting in the form of anemia, leukopenia 
or thrombocytopenia.
statistical analysis 
Statistical analysis for sensitivity and specificity 
of dosimetric parameters was performed using an 
ROC curve. The probability of developing bone 
marrow toxicity was analyzed using a T test. 
results
A total of 34 patients diagnosed to have squa-
mous cell Carcinoma of Cervix were treated by 
radical radiotherapy by IMRT and concurrent 
chemotherapy (weekly cisplatin 40 mg/m2). The 
median age was 54 years (39–73 years). The most 
common stage of presentation was stage IIB 
(61.7%). 
No patient experienced delays or breaks in pelvic 
RT because of acute toxicity. The median cispla-
tin dose per cycle was 60 mg. 29 patients (85.2%) 
completed five cycles of weekly cisplatin whereas 
four patients received four cycles and one patient 
received three cycles of chemotherapy. The mean 
PTV volume was 1248.2 cc and the mean bone 
marrow volume was 382.3 cc. The mean dose to the 
bone marrow was 29.5 Gy and the V20, V30 and 
V40 were 72.85%, 49.76% and 25.24%, respectively. 
hematologic toxicity
The incidence of Grade 1 acute hematologic 
toxicity was 41% whereas 50% patients developed 
Grade 2 toxicity during the course of treatment. 
None of the patients developed Grade 3 or 4 he-
matologic toxicities. There was a significant differ-
ence in the mean dose to the pelvic bone marrow 
between those who had developed overall haema-
tological toxicity of Grade 2 compared to those who 
had Grade 0 and Grade 1 toxicity (p = 0.001). The 
ROC curve showed that a cut-off level of 28.85 Gy 
mean dose had a sensitivity of 82.4% and a specific-
ity of 70.6% in classifying the overall toxicity level. 
Similar findings where noted with respect to mean 
dose to the pelvic bone marrow and anemia and 
leukopenia (Tab. 1 and 2).
The mean volumes of the bone marrow receiv-
ing 20, 30, 40 Gy i.e., V20, V30, V40, respectively, 
across different toxicity groups, i.e. anemia, leuko-
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penia and overall toxicity is as shown in Table 3. 
There was a significant difference between the two 
groups (with toxicity and without toxicity) among 
all types of toxicity (anemia, leukopenia and overall 
toxicity) across all the three pelvic bone marrow 
receiving radiation levels i.e., V20, V30 and V40 
except for V20 with anemia.
The obtained cut-off levels with respective sen-
sitivity and specificity in classifying the different 
toxicity groups with respect to the volume of bone 
marrow receiving V20, V30 and V40 are as re-
ported in Table 4 (except for V20 with anemia as 
there was no significant difference between toxicity 
groups).
With the cut-offs obtained from the ROC curve, 
relative risk was significant for overall toxicity 
across V20 and V30 and across V30 for anemia; 
whereas no significant risk was found for leukope-
nia (Tab. 5).
Discussion
The increasing use of IMRT in the treatment of 
carcinoma cervix has resulted in reduced treat-
ment related toxicities and improved quality of 
life. Various studies have demonstrated the superi-
ority of IMRT in providing reduced bone marrow 
doses as compared to 3DCRT [8, 9]. In resource 
limited countries like India, the burden of car-
cinoma cervix is high and patient affordability 
is a concern. Most of the patients of carcinoma 
cervix are treated with conventional four field 
and few with IMRT. Data is limited regarding the 
predictors of bone marrow toxicity in patients of 
table 2. cut-off points of mean dose to pelvic bone marrow on toxicity with its sensitivity and specificity
Type of toxicity Cut-off points (in Gy) Sensitivity (%) Specificity (%)
Overall toxicity 28.85 82.4 70.6
anemia 29.70 76.9 76.2
Leukopenia 29.70 85.7 66.7













present 75.6 ± 5.4
0.004
absent 70.1 ± 5.1
V30
present 54.7 ± 7.9
0.001
absent 44.0 ± 7.9
V40
present 31.0 ± 11.6
0.003





present 75.1 ± 5.5
0.096
absent 71.5 ± 5.8
V30
present 55.4 ± 8.2
0.004
absent 46.3 ± 8.2
V40
present 32.5 ± 11.9
0.003





present 78.8 ± 6.4
0.002
absent 71.3 ± 4.8
V30
present 56.8 ± 9.7
0.020
absent 47.9 ± 8.3
V40
present 33.1 ± 13.4
0.046
absent 23.2 ± 10.7
sD — standard deviation
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carcinoma cervix undergoing concurrent chemo-
radiation with IMRT. 
Our study demonstrated that the cutoff of 28.85 
Gy mean dose to bone marrow was significantly 
associated with Grade 2 or higher hematological 
toxicity in patients treated with concurrent chemo-
radiation with IMRT. The cut off values for V20, 
V30 and V40 were 71.75 Gy, 49.75 Gy and 22.85 
Gy, respectively. The incidence of acute grade 2 
hematological toxicity was 50% in our study. The 
percentage of patients developing Grade 2 leuko-
penia and anemia was 20.5% and 38.2%. Mell et 
al. [7] reported an association between the volume 
of whole-pelvis BM receiving low-dose radiation 
(V10 > 90 Gy and V20 > 75 Gy) and acute hemato-
logical toxicity. Overall, 25 patients (67.6%) experi-
enced leukopenia during treatment. The percentage 
of patients developing Grade 2 or worse leukope-
nia and anemia was 43.2% and 13.5%, respectively. 
This was in contrast to our patients who reported 
a higher incidence of anemia than leukopenia. Only 
59.5% patients received all planned chemotherapy, 
32.4% had one or more cycles held and 8.1% were 
noncompliant with the planned chemotherapy 
course. 85.2% patients received five cycles of weekly 
cisplatin in our study. 
A comparison of two different contouring meth-
ods on CT scan by Mahantshetty et al. [10] revealed 
that free hand contouring of inner cavity of the bone 
is a better surrogate of active bone marrow com-
pared to whole bone contouring. In our study, we 
used the free hand contouring method on planning 
CT. Data is emerging on the identification and spar-
ing of functional bone marrow to further reduce 
hematologic toxicities. Liang et al. [11] demonstrat-
ed favorable outcomes of a functional bone marrow 
sparing IMRT technique using 18F-FDG-PET, MRI 
and CT to identify functional BM. Another phase 2 
study published by Mell et al. [12] reported reduced 
incidence of acute neutropenia using PET CT based 
table 5. calculated relative risk (rr) with 95% confidence interval (cI) with cut-offs obtained from receiver operating 




Cut-off points RR 95% CI p-value
Overall toxicity
V20 ≥ 71.75 4.15 1.45–11.85 0.008
V30 ≥ 49.75 4.67 1.63–13.34 0.004
V40 ≥ 22.85 1.83 0.88–3.82 0.105
anemia
V20 – – – –
V30 ≥ 49.75 5.50 1.43–21.18 0.013
V40 ≥ 23.80 2.53 0.96–6.65 0.059
Leukopenia
V20 ≥ 72.20 3.17 0.71–14.10 0.130
V30 ≥ 51.20 3.57 0.80–15.86 0.094
V40 ≥ 24.65 3.17 0.71–14.10 0.130
table 4. cut-off points of mean irradiated bone marrow volumes on toxicity with its sensitivity and specificity
Type of toxicity Bone marrow volume Cut-off points (in %) Sensitivity (%) Specificity (%)
Overall toxicity
V20 71.75 82.4 76.5
V30 49.75 82.4 82.4
V40 22.85 64.7 64.7
anemia
V20 – – –
V30 49.75 84.6 71.4
V40 23.80 69.2 66.7
Leukopenia
V20 72.20 71.4 63.1
V30 51.20 71.4 66.7
V40 24.65 71.4 63.0
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bone marrow sparing IG-IMRT. The feasibility of 
utilizing the above techniques in resource limited 
settings and high volume centres is limited and 
needs further evaluation. 
Kumar T et al. evaluated the association between 
pelvic bone marrow dose volume parameters and 
the probability of acute hematological toxicity in 
a cohort of cervical cancer patients, receiving de-
finitive chemoradiation plus image-guided adaptive 
brachytherapy [13]. 114 patients were included of 
whom 75.4% were treated with 3D radiation thera-
py and 24.6% with IMRT. In multivariate analysis, 
grade 4 hematological toxicity was associated with 
lower pelvis V5 > 95%, lower pelvis V20 > 45%, to-
tal pelvic bone V20 > 65%, and iliac crests Dm > 31 
Gy. In patients treated by IMRT, G3+ leukopenia 
correlated with LS bone V30 > 91%, lower pelvis 
V15 > 65%, lower pelvis V20 > 48%, lower pelvis 
Dm > 21.7 Gy. Grade 3+ neutropenia correlated 
with LS bone V30 > 94%, iliac crest V20 > 84%, 
lower pelvis V15 > 65%. Grade 4 hematological 
toxicity was associated with lower pelvis V5 > 95% 
and lower pelvis V15 > 65%. Our patients did not 
report any Grade 3 or 4 hematological toxicities and 
we did not divide the bone marrow into different 
zones so a direct comparison with their results is 
difficult. We did not find any significant correla-
tion between volume of the bone marrow receiving 
lower doses of radiation (V5 and V15) and bone 
marrow toxicity. 
Our study is limited by a small sample size and 
inability to contour functional bone marrow. The 
strengths of our study are the use of IMRT for all 
patients and good compliance with chemotherapy. 
We believe this is the first study to report predictors 
of hematologic toxicity in carcinoma cervix patients 
receiving HDR brachytherapy along with chemo-
radiotherapy. The contribution of brachytherapy 
to active bone marrow is limited and needs to be 
evaluated in a prospective setting. These results can 
serve as a surrogate for carcinoma cervix patients 
treated with IMRT. This would help in predicting 
the course of acute toxicities in these patients and 
treating them effectively. 
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